The rise of Sildenafil initially drove a surge for pharma, nevertheless recent changes present a uncertain picture for shareholders. Off-patent competitors are eating into profits, and continued legal battles add more difficulty to the situation. While some companies might still see gains from complementary services, the general trend suggests a ca